Hashemi Mohammad, Hasanpour Vahed, Danesh Hiva, Bizhani Fatemeh, Narouie Behzad
Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Sistan and Baluchistan 98167-43181, Iran.
Department of Clinical Biochemistry, Zahedan University of Medical Sciences, Zahedan, Sistan and Baluchistan 98167-43181, Iran.
J Biomed Res. 2018 Sep 6;33(1):24-9. doi: 10.7555/JBR.31.20170044.
Several studies examined the impact of miR-34b/c rs4938723 polymorphism and cancer risk, but the findings are inconsistent. However, no study has been conducted to inspect the impact of miR-34b/c polymorphism on bladder cancer. This study aimed to assess possible association between rs4938723 polymorphism and bladder cancer risk. This case-control study was done on 136 pathologically proven bladder cancer patients and 144 controls. Genotyping of Pri-miR-34b/c rs4938723 polymorphism was achieved by using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. Our findings did not show any statistically significant differences in genotype and allele frequencies between bladder cancer and controls. Larger sample sizes with diverse ethnicities are required to validate our findings.
多项研究探讨了miR-34b/c rs4938723多态性与癌症风险之间的关系,但研究结果并不一致。然而,尚未有研究考察miR-34b/c多态性对膀胱癌的影响。本研究旨在评估rs4938723多态性与膀胱癌风险之间可能存在的关联。这项病例对照研究共纳入了136例经病理证实的膀胱癌患者和144例对照。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法对Pri-miR-34b/c rs4938723多态性进行基因分型。我们的研究结果显示,膀胱癌患者与对照组之间在基因型和等位基因频率上没有任何统计学显著差异。需要更大样本量和不同种族的研究来验证我们的研究结果。